Petros Pharmaceuticals, Inc. Research and Development Expense
Petros Pharmaceuticals, Inc. (PTPI) reported Research and Development Expense of $2.62 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. research and development expense for the quarter ending 2024-12-31 was $101.94K, a 87.78% decline year-over-year.
- Petros Pharmaceuticals, Inc. research and development expense for the quarter ending 2024-09-30 was $588.36K, a 51.21% increase year-over-year.
- Petros Pharmaceuticals, Inc. research and development expense for the quarter ending 2024-06-30 was $368.80K, a 57.44% decline year-over-year.
- Petros Pharmaceuticals, Inc. research and development expense for the quarter ending 2024-03-31 was $1.56M, a 387.62% increase year-over-year.
- Petros Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $2.62M, a 8.55% increase from fiscal 2023.
- Petros Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $2.41M, a 38.43% increase from fiscal 2022.
- Petros Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $1.74M, a 2.70% decline from fiscal 2021.
- Petros Pharmaceuticals, Inc. research and development expense for fiscal 2021 was $1.79M, a 289.11% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $101.94K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $690.30K derived: sum of 2 quarters · filed 2025-03-31 | $1.06M derived: sum of 3 quarters · filed 2025-03-31 | $2.62M 10-K · filed 2025-03-31 |
| 2024-09-30 | $588.36K 10-Q · filed 2024-11-13 | $957.15K derived: sum of 2 quarters · filed 2024-11-13 | $2.51M 10-Q · filed 2024-11-13 | $3.35M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $368.80K 10-Q · filed 2024-08-14 | $1.92M 10-Q · filed 2024-08-14 | $2.76M derived: sum of 3 quarters · filed 2025-03-31 | $3.15M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $1.56M 10-Q · filed 2024-05-15 | $2.39M derived: sum of 2 quarters · filed 2025-03-31 | $2.78M derived: sum of 3 quarters · filed 2025-03-31 | $3.65M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $834.33K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.22M derived: sum of 2 quarters · filed 2025-03-31 | $2.09M derived: sum of 3 quarters · filed 2025-03-31 | $2.41M 10-K · filed 2025-03-31 |
| 2023-09-30 | $389.09K 10-Q · filed 2024-11-13 | $1.26M derived: sum of 2 quarters · filed 2024-11-13 | $1.57M 10-Q · filed 2024-11-13 | $1.75M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $866.58K 10-Q · filed 2024-08-14 | $1.19M 10-Q · filed 2024-08-14 | $1.36M derived: sum of 3 quarters · filed 2024-08-14 | $2.10M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $319.09K 10-Q · filed 2024-05-15 | $496.86K derived: sum of 2 quarters · filed 2024-05-15 | $1.23M derived: sum of 3 quarters · filed 2024-05-15 | $1.65M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $177.76K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $913.68K derived: sum of 2 quarters · filed 2024-04-01 | $1.33M derived: sum of 3 quarters · filed 2024-04-01 | $1.74M 10-K · filed 2024-04-01 |
| 2022-09-30 | $735.92K 10-Q · filed 2023-11-15 | $1.16M derived: sum of 2 quarters · filed 2023-11-15 | $1.56M 10-Q · filed 2023-11-15 | $2.55M derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | $421.24K 10-Q · filed 2023-08-14 | $826.60K 10-Q · filed 2023-08-14 | $1.82M derived: sum of 3 quarters · filed 2023-08-14 | $2.10M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $405.36K 10-Q · filed 2023-05-15 | $1.39M derived: sum of 2 quarters · filed 2023-05-15 | $1.67M derived: sum of 3 quarters · filed 2023-05-15 | $2.17M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $988.69K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $1.27M derived: sum of 2 quarters · filed 2023-03-31 | $1.77M derived: sum of 3 quarters · filed 2023-03-31 | $1.79M 10-K · filed 2023-03-31 |
| 2021-09-30 | $280.58K 10-Q/A · filed 2022-11-15 | $780.62K derived: sum of 2 quarters · filed 2022-11-15 | $799.80K 10-Q/A · filed 2022-11-15 | $951.64K derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | $500.05K 10-Q · filed 2022-08-12 | $519.23K 10-Q · filed 2022-08-12 | $671.07K derived: sum of 3 quarters · filed 2022-08-12 | $707.89K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $19.18K 10-Q · filed 2022-05-16 | $171.02K derived: sum of 2 quarters · filed 2022-05-16 | $207.85K derived: sum of 3 quarters · filed 2022-05-16 | $339.43K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $151.84K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $188.67K derived: sum of 2 quarters · filed 2022-03-31 | $320.25K derived: sum of 3 quarters · filed 2022-03-31 | $459.64K 10-K · filed 2022-03-31 |
| 2020-09-30 | $36.83K 10-Q · filed 2021-11-15 | $168.41K derived: sum of 2 quarters · filed 2021-11-15 | $307.80K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $131.58K 10-Q · filed 2021-08-16 | $270.97K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $139.38K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |